{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:10:39Z","timestamp":1792113039249,"version":"4.4.0"},"reference-count":40,"publisher":"Massachusetts Medical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NEJM Evidence"],"published-print":{"date-parts":[[2022,1,9]]},"DOI":"10.1056\/evidoa2100001","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T22:20:18Z","timestamp":1640211618000},"source":"Crossref","is-referenced-by-count":79,"title":["Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers"],"prefix":"10.1056","volume":"1","author":[{"given":"Michael L.","family":"Wang","sequence":"first","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline C.","family":"Barrientos","sequence":"additional","affiliation":[{"name":"Northwell Health System, New Hyde Park, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Furman","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Mei","sequence":"additional","affiliation":[{"name":"City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9733-401X","authenticated-orcid":false,"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[{"name":"University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Y.","family":"Choi","sequence":"additional","affiliation":[{"name":"University of California, San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"de Vos","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avyakta","family":"Kallam","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2446-098X","authenticated-orcid":false,"given":"Krish","family":"Patel","sequence":"additional","affiliation":[{"name":"Swedish Cancer Institute, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"University of California, San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rule","sequence":"additional","affiliation":[{"name":"VelosBio, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Flanders","sequence":"additional","affiliation":[{"name":"VelosBio, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katti A.","family":"Jessen","sequence":"additional","affiliation":[{"name":"VelosBio, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[{"name":"VelosBio, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Riebling","sequence":"additional","affiliation":[{"name":"VelosBio, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Graham","sequence":"additional","affiliation":[{"name":"Catalyst Clinical Research, Wilmington, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"King","sequence":"additional","affiliation":[{"name":"Catalyst Clinical Research, Wilmington, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archie W.","family":"Thurston","sequence":"additional","affiliation":[{"name":"ADME Solutions, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sun","sequence":"additional","affiliation":[{"name":"VelosBio, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"VelosBio, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Lannutti","sequence":"additional","affiliation":[{"name":"VelosBio, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Johnson","sequence":"additional","affiliation":[{"name":"VelosBio, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Langdon L.","family":"Miller","sequence":"additional","affiliation":[{"name":"VelosBio, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Spurgeon","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5904"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2012.12.009"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-017-0512-y"},{"key":"e_1_3_5_5_2","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: B-cell lymphomas. Version 3.2021. March 16 2021 (https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf)."},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3222.3222"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15170"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0209-5"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15412"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25505"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-014-0059-7"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2014.07.005"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2015.1025753"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.731599"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031127"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-712562"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/biof.1498"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801327"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-016-1911-3"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep36447"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.02.010"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2018.05.018"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119447"},{"key":"e_1_3_5_25_2","first-page":"33","article-title":"Targeting ROR1 using the antibody drug conjugate VLS-101 in aggressive mantle cell lymphoma","volume":"136","year":"2020","unstructured":"Jiang VC, Liu Y, McIntosh J, et al. Targeting ROR1 using the antibody drug conjugate VLS-101 in aggressive mantle cell lymphoma. Blood 2020;136(Suppl 1):33.","journal-title":"Blood"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008404"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70128-2"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08143.x"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0712148105"},{"key":"e_1_3_5_35_2","unstructured":"Seattle Genetics. Adcetris\u00ae (brentuximab vedotin) prescribing information. October 2019 (https:\/\/seagendocs.com\/Adcetris_Full_Ltr_Master.pdf)."},{"key":"e_1_3_5_36_2","unstructured":"Genentech-Roche. Polivy\u00ae (polatuzumab vedotin-piiq) prescribing information. September 2019 (https:\/\/www.gene.com\/download\/pdf\/polivy_prescribing.pdf)."},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0133"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1605068"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12442"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2083"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2015.01.014"}],"container-title":["NEJM Evidence"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T18:12:27Z","timestamp":1651169547000},"score":1,"resource":{"primary":{"URL":"https:\/\/evidence.nejm.org\/doi\/10.1056\/EVIDoa2100001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,9]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,9]]}},"alternative-id":["10.1056\/EVIDoa2100001"],"URL":"https:\/\/doi.org\/10.1056\/evidoa2100001","relation":{},"ISSN":["2766-5526"],"issn-type":[{"value":"2766-5526","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,9]]}}}